Hashimoto’s thyroiditis is the most common form of autoimmune thyroiditis and is characterized by a chronic lymphocytic inflammatory process affecting the thyroid parenchyma, with progressive follicular loss, variable fibrotic remodeling, and a reduction in functional reserve that may eventually lead to clinically overt hypothyroidism. Biologically, the disease results from a breakdown of immune tolerance toward thyroid-specific antigens, particularly thyroid peroxidase and thyroglobulin, with coordinated activation of cellular and humoral immunity. Although the thyroid gland may initially compensate and maintain euthyroidism, it progressively loses its ability to organify iodine and synthesize and secrete thyroid hormones. The course may be slow and insidious, and clinical manifestations often emerge only when thyrotropic stimulation can no longer offset the reduction in functioning follicular mass.
Clinically, Hashimoto’s thyroiditis does not always coincide with overt hypothyroidism. A substantial proportion of patients are euthyroid at diagnosis and are identified because of antibody positivity and a suggestive ultrasound pattern, whereas others present with subclinical or overt hypothyroidism. During the early stages or inflammatory exacerbations, transient thyrotoxicosis caused by follicular destruction may occur. This condition, commonly termed hashitoxicosis, does not result from sustained hormone overproduction but from the release of preformed thyroid hormones.
Hashimoto’s thyroiditis is among the most common autoimmune diseases and represents a leading cause of primary hypothyroidism in areas with adequate iodine intake. Its actual epidemiology is influenced by the widespread use of biochemical screening, thyroid antibody testing, and ultrasonography, which allow early and paucisymptomatic forms to be identified. The disease shows a marked female predominance and usually begins in adulthood, although it may occur at any age, including childhood and adolescence, when hypothyroidism may interfere with growth, pubertal development, and academic performance.
Among the main risk factors, genetic predisposition is particularly important and manifests as a family history of autoimmune thyroid disease or, more broadly, organ-specific autoimmune disorders. Susceptibility is polygenic and involves genes related to antigen presentation and regulation of the immune response, with an important contribution from human leukocyte antigen (HLA) profiles and variants in immunoregulatory genes that modulate lymphocyte activation and the physiological checkpoints of peripheral tolerance. This genetic background does not determine the disease in a deterministic manner but establishes a window of vulnerability in which environmental factors may trigger or accelerate the autoimmune process.
Among environmental factors, iodine intake deserves particular attention. A relative excess of iodine may increase the immunogenicity of thyroid proteins and promote intrathyroidal oxidative stress, facilitating the exposure of neoepitopes and antigen presentation. This does not imply that iodine is the sole cause of the disease or that indiscriminate iodine restriction is beneficial. It does, however, explain why the transition from iodine deficiency to iodine sufficiency may alter the distribution of thyroid disorders and facilitate the clinical emergence of latent autoimmunity in predisposed subgroups.
Another epidemiologically important factor is the immune modulation associated with pregnancy and the postpartum period. After delivery, restoration of immune reactivity following pregnancy may promote the onset or exacerbation of thyroid autoimmunity, producing clinical patterns that overlap with postpartum thyroiditis and that, in some women, progress to persistent Hashimoto’s thyroiditis with stable hypothyroidism. This scenario is clinically relevant because symptoms may be mistaken for postpartum fatigue or mood disorders, delaying diagnosis and treatment.
The association with other autoimmune diseases is an integral component of the clinical epidemiology of Hashimoto’s thyroiditis. Coexistence with type 1 diabetes mellitus, celiac disease, autoimmune gastritis and pernicious anemia, vitiligo, and other autoimmune endocrinopathies within polyglandular syndromes is common. These associations are not merely comorbidities but indicate a shared immunological background that increases the likelihood of additional diagnoses over time and influences screening and follow-up strategies. In the therapeutic setting, medications that modulate the immune response, including oncological immunotherapies, may promote autoimmune thyroid dysfunction or destructive thyroiditis progressing to permanent hypothyroidism, thereby overlapping with the Hashimoto phenotype in predisposed individuals.
The etiology of Hashimoto’s thyroiditis is multifactorial and results from the interaction between genetic susceptibility and environmental factors, leading to a breakdown of immune tolerance toward thyroid-specific antigens. The thyroid becomes the site of a chronic immune response in which antigen-presenting cells and T and B lymphocytes cooperate to sustain inflammation. A key event is the activation of helper T lymphocytes with predominantly pro-inflammatory polarization, accompanied by cytokine production that amplifies cellular recruitment and tissue injury. At the same time, B lymphocytes differentiate into plasma cells and produce autoantibodies, particularly thyroid peroxidase antibodies and thyroglobulin antibodies, which are important diagnostic markers and reflect the intensity of humoral autoimmunity.
The follicular damage observed in Hashimoto’s thyroiditis is primarily driven by cellular immune mechanisms and cytotoxicity rather than by the direct action of autoantibodies as toxins in the strict sense. The intrathyroidal lymphocytic infiltrate may organize into lymph node-like structures containing germinal centers, indicating a sustained local adaptive immune response. Thyrocytes exposed to pro-inflammatory cytokines increase the expression of molecules involved in antigen presentation and become targets of apoptosis and T lymphocyte-mediated cytotoxicity. Activation of apoptotic pathways, including Fas/Fas ligand interactions in inflammatory settings, contributes to the progressive loss of functioning follicular cells. Stromal remodeling and fibrosis, which vary among patients, determine whether the disease progresses toward a small, scarred thyroid gland or, conversely, toward persistent lymphocytic goiter.
From a pathophysiological perspective, the disease may be described as a continuum between functional compensation and decompensation. Initially, follicular loss and biosynthetic inefficiency are compensated for by increased thyrotropic stimulation, with thyroid-stimulating hormone (TSH) levels gradually rising to maintain adequate production of thyroxine (T4) and triiodothyronine (T3). This stage frequently corresponds to subclinical hypothyroidism, in which free thyroxine (FT4) remains within the reference range but thyroid reserve is reduced. As tissue injury progresses, the gland’s ability to respond to TSH stimulation declines and FT4 levels decrease, resulting in overt hypothyroidism. During this transition, symptoms often emerge gradually and may be amplified by concomitant factors such as anemia, iron or vitamin B12 deficiency, depression, pregnancy, or cardiovascular disease.
Hashitoxicosis results from episodes of follicular destruction that release preformed thyroid hormones from the colloid into the circulation. Because there is no sustained increase in hormone synthesis, this phase is usually self-limiting and may be followed by a period of more pronounced hypothyroidism once hormone stores are depleted. The pathophysiological distinction between thyrotoxicosis caused by hormone release and thyrotoxicosis caused by overproduction is essential because it guides both investigations and treatment. In hashitoxicosis, the objective is to control adrenergic symptoms and monitor the clinical course rather than inhibit thyroid hormone synthesis with antithyroid medications, except in unusual situations in which the differential diagnosis remains unresolved.
Another pathogenetic aspect concerns the interaction between thyroid autoimmunity and the endocrine system as a whole. In the presence of other autoimmune endocrinopathies, the immune environment is more unstable and the likelihood of functional progression increases. In addition, conditions that alter thyroid hormone homeostasis, such as changes in thyroxine-binding globulin concentrations, pregnancy, or medication use, may reveal a previously compensated reduction in thyroid reserve. This explains why Hashimoto’s thyroiditis may remain clinically silent for years and subsequently become apparent during periods of increased hormonal requirements or immune remodeling.
The clinical presentation of Hashimoto’s thyroiditis is highly variable and depends on thyroid functional status, the rate of disease progression, and the presence of goiter or fluctuating inflammatory phases. Many patients report gradually developing symptoms of hypothyroidism, including persistent fatigue, reduced physical and mental performance, somnolence, cold intolerance, weight gain that is not always proportional to caloric intake, constipation, dry skin, and brittle hair. Mood changes, reduced motivation, and difficulty concentrating may also occur and are frequently attributed to stress or primary depression, particularly when physical signs are subtle.
In women, hypothyroidism may be associated with menstrual irregularities, reduced fertility, and an increased risk of obstetric complications when it is not recognized and treated appropriately. During pregnancy and the postpartum period, symptoms may be obscured by physiological changes. Nevertheless, autoimmune thyroid disease is clinically relevant in this setting because the increased requirement for thyroid hormone may exceed the residual thyroid reserve and result in hypothyroidism requiring prompt treatment. In children and adolescents, the presentation may include growth retardation, delayed puberty, fatigue, and reduced academic performance, with physical signs that may be less apparent than the functional consequences.
On physical examination, a common finding is a diffuse goiter, usually painless, with increased consistency and a smooth or mildly irregular surface. In other forms, particularly during advanced stages, the thyroid gland may be small and fibrotic, with more pronounced clinical signs of hypothyroidism. In patients with hashitoxicosis, symptoms may be dominated by palpitations, fine tremor, anxiety, and heat intolerance, but generally without the typical features of autoimmune hormone overproduction, such as orbitopathy. This finding supports the differential diagnosis but requires laboratory and, when necessary, antibody confirmation.
Clinical signs of hypothyroidism include relative bradycardia, delayed relaxation of deep tendon reflexes, dry skin, non-pitting edema, and hoarseness, although their presence depends on the duration and severity of hormone deficiency. Many patients have a subtle clinical picture in which the main effects involve quality of life, lipid metabolism, and exercise tolerance. In some cases, compression caused by goiter may lead to dysphagia, a sensation of neck fullness, or exertional dyspnea, making accurate anatomical and functional assessment necessary to distinguish mass effect from the systemic symptoms of hypothyroidism.
Hashimoto’s thyroiditis is frequently accompanied by autoimmune comorbidities that contribute to the clinical presentation. Iron deficiency anemia or megaloblastic anemia caused by autoimmune gastritis may worsen fatigue and dyspnea. Celiac disease may interfere with micronutrient absorption and, in patients receiving replacement therapy, with the absorption of levothyroxine. In these situations, clinical assessment should reconstruct a coherent temporal sequence of symptoms and integrate the findings into a unified clinical picture, avoiding an overly reductive attribution to a single endocrine axis.
Hashimoto’s thyroiditis should be suspected when a patient presents with signs or symptoms consistent with hypothyroidism, particularly when they are associated with a painless goiter, a family history of autoimmune thyroid disease, or other autoimmune disorders. Suspicion is especially strong when hypothyroidism has been newly diagnosed in an iodine-sufficient area and there are no evident iatrogenic causes such as thyroidectomy, radioactive iodine treatment, or medications known to induce hypothyroidism. In these cases, thyroid autoantibody positivity and a typical ultrasound pattern provide confirmatory evidence, although the decision to test for antibodies should be based on clinical reasoning rather than indiscriminate screening.
Hashimoto’s thyroiditis should also be suspected in euthyroid patients with a diffuse goiter or a suggestive thyroid ultrasound pattern, particularly when the clinical history includes fluctuations in TSH over time or a progressive increase in thyrotropic stimulation. Suspicion is particularly relevant in women of reproductive age and in those planning pregnancy, because a reduced thyroid reserve may become clinically significant as gestational hormone requirements increase and because thyroid autoimmunity is associated with a higher likelihood of thyroid dysfunction during pregnancy and the postpartum period.
A common clinical setting is the evaluation of dyslipidemia and weight gain. An elevated TSH concentration may be interpreted as a consequence of obesity or chronic stress, but in the presence of autoimmunity and reduced thyroid reserve, the primary problem may be endocrine. Similarly, fatigue, cognitive slowing, and depressed mood warrant consideration of autoimmune hypothyroidism as a potentially reversible cause, particularly when physical signs, family history, or autoimmune comorbidities are present.
Hashitoxicosis should be suspected when thyrotoxicosis occurs without neck pain and without the typical features of Graves’ disease, particularly when there is a previous history of elevated TSH, high thyroid peroxidase antibody concentrations, or ultrasound findings consistent with chronic thyroiditis. In this setting, the main clinical risk is misinterpreting thyrotoxicosis as hormone overproduction and initiating unnecessary antithyroid therapy, thereby delaying symptomatic control and appropriate surveillance for the subsequent hypothyroid phase.
Finally, Hashimoto’s thyroiditis should be considered in patients with signs and symptoms of other systemic or organ-specific autoimmune diseases, because thyroid autoimmunity may be one component of a broader disorder. In such cases, identifying thyroid involvement is important not only for treating hypothyroidism but also for explaining nonspecific symptoms and establishing integrated follow-up aimed at reducing diagnostic delays for common comorbidities such as celiac disease and autoimmune gastritis.
The diagnosis of Hashimoto’s thyroiditis is based on the integration of clinical, biochemical, and immunological findings, supported by thyroid ultrasonography when indicated. The initial assessment consists of thyroid function testing with thyroid-stimulating hormone (TSH) and free thyroxine (FT4). An elevated TSH concentration with reduced FT4 defines overt hypothyroidism, whereas an elevated TSH concentration with FT4 within the reference range indicates subclinical hypothyroidism. In both cases, identification of an autoimmune cause requires testing for thyroid autoantibodies, particularly thyroid peroxidase antibodies and, as a complementary marker, thyroglobulin antibodies. Thyroid peroxidase antibody positivity is the most informative marker of thyroid autoimmunity and is associated with the risk of progression to hypothyroidism over time, although it does not correlate linearly with clinical severity at a specific point in time.
Thyroid ultrasonography is particularly useful when goiter is present, palpation findings are uncertain, nodules are detected, or morphological confirmation is required in patients with autoantibodies and early thyroid dysfunction. The typical pattern includes reduced echogenicity, diffuse heterogeneity, and occasionally pseudonodularity caused by fibrous septa and lymphocytic infiltration. Doppler vascularity may be increased or variable and should be interpreted within the clinical context, because hyperemia is more pronounced in some hyperfunctioning conditions and is less specific in chronic thyroiditis. Ultrasonography also allows the identification of true nodules requiring a separate risk-stratification pathway and, when indicated, fine-needle aspiration.
The differential diagnosis includes non-autoimmune causes of primary hypothyroidism, iatrogenic hypothyroidism, and central forms. When the biochemical pattern is atypical, such as low FT4 with a TSH concentration that is not elevated, central hypothyroidism should be considered and the hypothalamic-pituitary axis should be evaluated. During episodes of hashitoxicosis, the main differential diagnoses are Graves’ disease and other forms of destructive thyroiditis that are not necessarily chronic. In these cases, thyrotropin receptor antibodies, the ultrasound pattern, and, when appropriate, functional tests such as radioactive iodine uptake help distinguish hormone overproduction from destructive release. Correct interpretation is essential because the therapeutic strategy differs substantially.
When nodules or rapid thyroid enlargement are present, a diagnosis of Hashimoto’s thyroiditis does not exclude concomitant disease. Chronic inflammation may coexist with benign nodules and, rarely, thyroid neoplasms. In addition, when the thyroid is markedly enlarged or firm, or when progressive compressive symptoms are present, alternative diagnoses such as thyroid lymphoma or fibrosing thyroiditis should be considered and targeted investigations should be performed. In these situations, fine-needle aspiration and any subsequent cytological or histological assessment are guided by clinical risk and imaging findings rather than by the presence of autoantibodies alone.
The diagnostic assessment should also include functional factors that influence management and follow-up. In patients with autoimmune hypothyroidism, evaluation of the lipid profile is reasonable, as is screening for common autoimmune comorbidities when suggested by the clinical history. The aim is not to expand testing indiscriminately but to recognize that pernicious anemia or celiac disease may explain persistent symptoms and interfere with the response to replacement therapy, creating the false impression of treatment-resistant hypothyroidism when the actual problem is extrathyroidal or related to impaired medication absorption.
Hashimoto’s thyroiditis encompasses a spectrum of clinical forms that share the same autoimmune mechanism but differ in morphology, functional status, and clinical course. A practical classification distinguishes euthyroid autoimmune thyroiditis, subclinical hypothyroidism, overt hypothyroidism, forms with persistent goiter, and atrophic forms characterized by reduced thyroid volume and fibrosis. The euthyroid form is frequently identified through antibody positivity and a typical ultrasound pattern and requires surveillance because reduced thyroid reserve may become clinically apparent over time. Subclinical and overt forms represent stages of progressive functional decompensation and have different therapeutic implications depending on symptoms, age, cardiovascular risk, and reproductive context.
A clinically relevant functional variant is hashitoxicosis, in which chronic thyroiditis may produce periods of thyrotoxicosis caused by hormone release. These episodes are usually self-limiting and may be followed by more pronounced hypothyroidism. Hashitoxicosis is not a separate disease but a temporal manifestation of follicular injury in an autoimmune setting and must be distinguished from autoimmune hyperthyroidism caused by hormone overproduction because the therapeutic consequences are immediate.
Severity may be assessed on several levels. Biochemically, the severity of hypothyroidism is defined by the reduction in FT4 and the increase in TSH, although the correlation with symptoms is imperfect and depends on disease duration and individual sensitivity. Clinically, severity is determined by the impact on cardiovascular function, metabolism, neuropsychiatric status, and quality of life, as well as by the presence of compressive goiter. Prognostically, severity depends on the likelihood of irreversible progression and on the presence of autoimmune comorbidities that increase management complexity and the probability of additional diagnoses over time.
The main clinical and functional forms of Hashimoto’s thyroiditis can be arranged along an evolutionary spectrum reflecting the progressive impact of autoimmunity on thyroid structure and function:
Clinical and functional classification
This classification is useful because it links morphology and function to clinical decisions. The euthyroid form requires surveillance, overt hypothyroidism requires replacement therapy, subclinical forms require risk stratification, and hashitoxicosis requires symptomatic treatment and monitoring of the clinical course rather than systematic antithyroid therapy. The distinction between forms associated with compressive goiter and atrophic forms is also relevant to local management and to the need for targeted ultrasound follow-up when nodules or compressive symptoms coexist.
The treatment of Hashimoto’s thyroiditis focuses on correcting its functional consequences, particularly hypothyroidism, and managing situations in which the disease causes thyroid instability or compressive problems. The standard treatment for hypothyroidism is levothyroxine, which replaces deficient thyroid hormone and allows normalization of TSH and clinical improvement in the large majority of patients. The dose must be individualized according to age, body weight, cardiovascular comorbidities, severity of hypothyroidism, and the overall clinical setting. In older patients or those with cardiovascular disease, treatment should be introduced cautiously and increased progressively to reduce the risk of ischemia or arrhythmias. In younger individuals without comorbidities, the effective dose may be reached more rapidly, while still performing biochemical reassessment after an appropriate interval.
In overt hypothyroidism, replacement therapy is generally indicated because the risk of persistent symptoms and metabolic complications outweighs the risks of treatment. In subclinical hypothyroidism, the decision is more complex and should integrate the degree of TSH elevation, symptoms, antibody status, goiter, age, cardiovascular risk, and reproductive goals. Persistently and substantially elevated TSH, symptoms attributable to hypothyroidism, and pregnancy planning or ongoing pregnancy make treatment more likely to be indicated. In other cases, surveillance with periodic reassessment may be appropriate.
The management of hashitoxicosis is primarily symptomatic. Because thyrotoxicosis results from the release of preformed hormones rather than sustained hormone overproduction, treatment with antithyroid medications is generally inappropriate. The objective is to control adrenergic symptoms with beta-blockers when necessary and to monitor disease evolution, because the hyperfunctioning phase usually resolves and may be followed by hypothyroidism requiring evaluation for levothyroxine therapy. In patients at high cardiovascular risk, even transient thyrotoxicosis requires careful management, with priority given to hemodynamic stability and symptom control.
In some patients, particularly those with substantial goiter or compressive symptoms, replacement therapy may reduce thyrotropic stimulation and help stabilize thyroid volume. However, its effect on goiter is variable and depends on the degree of fibrosis and disease duration. When nodules coexist or significant compressive signs are present, management should be individualized and may include surgical assessment, not to treat the autoimmune process itself but to resolve local problems and ensure an accurate diagnosis when oncological concerns exist.
Among additional interventions, selenium supplementation has been studied primarily for its potential to reduce antibody concentrations. However, whether this effect translates into robust clinical benefits or prevention of functional progression has not been universally demonstrated. Its use should therefore be cautious, clinically contextualized, and consistent with the patient’s nutritional status and the long-term safety of the administered dose. When celiac disease or another condition interfering with absorption is present, dietary management is indicated for the underlying disorder. In individuals without documented celiac disease, dietary restrictions unsupported by a specific diagnosis do not replace replacement therapy and may introduce nutritional risks without clear benefits.
Follow-up in Hashimoto’s thyroiditis is intended to maintain stable thyroid function, identify disease progression at an early stage, and manage conditions that may interfere with treatment effectiveness. In patients receiving levothyroxine, the main monitoring parameter is thyroid-stimulating hormone (TSH), interpreted together with FT4 when necessary. Testing should be performed at appropriate intervals after dose changes and periodically once the condition is stable. Because levothyroxine requires time to reach a new steady state, excessively frequent testing may lead to unnecessary dose adjustments and iatrogenic instability.
An essential practical consideration is the assessment of administration timing and factors that alter absorption, including binding medications, iron and calcium supplements, proton pump inhibitors, and gastrointestinal disorders. In patients with unexplained TSH fluctuations or unusually high dose requirements, medication interactions, adherence, and conditions such as celiac disease or autoimmune gastritis should be considered. This approach prevents treatment-resistant hypothyroidism from being diagnosed when the actual cause is often a pharmacokinetic variable or an unrecognized comorbidity.
In euthyroid patients with thyroid autoimmunity or in those with subclinical hypothyroidism managed through surveillance, follow-up is aimed at detecting a progressive increase in TSH and the development of consistent symptoms, particularly during periods of increased hormonal requirements such as pregnancy. In women planning pregnancy or already pregnant, monitoring should be more frequent. If levothyroxine is already being used, an early dose adjustment is often required because hormone requirements increase during the first weeks of gestation. During the postpartum period, thyroid function should be reassessed because immune modulation may cause substantial changes and levothyroxine requirements may differ from those during pregnancy.
Thyroid ultrasonography is not a routine monitoring test for every patient with Hashimoto’s thyroiditis. It is indicated when nodules, changes in thyroid volume, compressive symptoms, or uncertain palpation findings are present. Chronic thyroiditis may make the parenchyma heterogeneous and produce pseudonodularity. Ultrasound interpretation should therefore be performed by an experienced operator, and when a true suspicious nodule is identified, it should be managed according to standard risk criteria, including fine-needle aspiration when appropriate. Serial measurement of thyroid autoantibodies is generally not useful for guiding replacement therapy because treatment decisions are based on thyroid function and symptoms rather than on the antibody concentration at a single point in time.
Finally, follow-up should include an integrated approach to comorbidities, including assessment of cardiovascular risk and lipid profile in patients with hypothyroidism, attention to signs of other autoimmune diseases, and periodic review of concomitant medications. Functional prognosis depends not only on TSH control but also on management of the overall clinical context that may amplify or reduce the effects of hypothyroidism and its treatment.
The prognosis of Hashimoto’s thyroiditis is generally favorable when hypothyroidism is recognized and treated appropriately, because levothyroxine replacement therapy allows functional normalization and a good quality of life in most patients. Nevertheless, the disease has a chronic course, and in forms associated with progressive loss of thyroid parenchyma, the need for replacement therapy is usually permanent. In patients who are initially euthyroid, prognosis depends on thyroid reserve and the intensity of the autoimmune process. Some remain stable for years, whereas others progress to subclinical and subsequently overt hypothyroidism, particularly when thyroid peroxidase antibody concentrations are high and the ultrasound pattern is markedly abnormal.
A clinically important complication is functional fluctuation, with episodes of hashitoxicosis followed by more pronounced hypothyroidism. These fluctuations may produce alternating symptoms and lead to unnecessary therapeutic changes when the underlying pathophysiology is not recognized. Another group of complications includes the consequences of untreated or undertreated hypothyroidism, such as dyslipidemia, increased cardiovascular risk, reduced physical and cognitive performance, and, in severe and prolonged cases, advanced hypothyroidism with multiorgan impairment. Conversely, excessive levothyroxine treatment may cause iatrogenic effects, including tachycardia, loss of bone mass, and an increased risk of arrhythmias, particularly in older patients. Follow-up based on realistic therapeutic targets and patient safety is therefore essential.
Hashimoto’s thyroiditis is associated with an increased risk of other autoimmune disorders, which represent a systemic complication rather than a direct thyroid event. In clinical practice, pernicious anemia, celiac disease, or type 1 diabetes mellitus may emerge over time and explain persistent symptoms despite adequate TSH control. This requires reasoned clinical vigilance directed toward warning signs, while avoiding both under-recognition and indiscriminate over-screening.
From an oncological perspective, chronic thyroid inflammation has been associated in the literature with an increased risk of thyroid lymphoma, which is rare but clinically important. In practice, findings that should increase clinical vigilance include rapid thyroid enlargement, the appearance of a firm mass, progressive compressive symptoms, or suspicious lymph nodes rather than the presence of autoantibodies alone. The association between Hashimoto’s thyroiditis and papillary thyroid carcinoma has been extensively investigated, with inconsistent findings. The clinically relevant principle is that thyroiditis does not replace standard criteria for nodule assessment and should not delay diagnostic evaluation when a nodule has suspicious characteristics.
In summary, Hashimoto’s thyroiditis is a chronic disease with substantial epidemiological impact and generally favorable outcomes when managed systematically. Management requires early recognition of reduced thyroid reserve, individualized replacement therapy, prevention of overtreatment, particular attention during reproductive stages, and integrated assessment of autoimmune comorbidities. Individual prognosis depends less on antibody positivity itself than on functional evolution and the quality of long-term follow-up.